Full-Time

Scientist II

Computational Biology

Posted on 9/26/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing therapies for cardiovascular disease

Biotechnology
Healthcare

Mid, Senior

Boston, MA, USA

Hybrid role requiring 3 days in the Boston office.

Category
Computational Biology
Biology & Biotech
Required Skills
Python
R
Data Analysis
Requirements
  • Ph.D. in computational biology, systems biology, bioinformatics or related fields with 2+ years of relevant industry experience or;
  • M.S. in computational biology, systems biology, bioinformatics or related fields with 7+ years of relevant industry experience or;
  • B.S. in computational biology, systems biology, bioinformatics or related fields with 9+ years of relevant industry experience.
  • In depth knowledge of in NGS data analysis, e.g., for targeted amplicon sequencing, genome-wide sequencing, variant calling.
  • Working knowledge of commonly used statistical approaches.
  • Proficient in Python and/or R programming languages.
  • Proven experience with tools and frameworks for reproducible scientific research, demonstrated by a strong publication record reflecting relevant research expertise.
  • Proven ability to thrive in a collaborative team setting, formulating research questions, developing methodologies, and analyzing and interpreting results.
  • Exceptional analytical and problem-solving skills, with strong communication and interpersonal abilities.
  • Collaborative, detail-oriented mindset, adept at efficiently working across multiple teams and projects in a matrixed environment.
Responsibilities
  • Perform data analysis of gene editing outcomes using state-of-the-art methods and tools.
  • Collaborate with cross-functional teams providing input to the experimental design and data interpretation.
  • Develop novel methods for NGS-based on- and off-target analysis, and high-throughput screens, incorporating appropriate statistical analyses as needed.
  • Coordinate activities and timelines through close collaboration with the laboratory head and other staff
  • Effectively communicate analysis results to key technical and non-technical stakeholders.
  • Maintain scientific and technical expertise through familiarity with scientific literature.
  • Mentor junior team members.
  • Research and evaluate new methods and technologies for continual process improvement with the goal of developing robust and scalable processes.
  • Ensure effective, high quality, timely and appropriate documentation. Recording, analyzing, and documenting data and results appropriately.
  • Interpret data, documents, study results and presentation of data and conclusions to diverse function groups. May author development reports, study protocols and pre-validation reports.
  • Troubleshoot scientific and technical challenges and contribute to their resolution.
  • Other duties as assigned.

Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions rather than ongoing management. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from traditional therapies that require continuous treatment. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular conditions, improving their long-term health outcomes.

Company Stage

IPO

Total Funding

$353.6M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Eli Lilly's $60M investment indicates strong market interest in Verve's therapies.
  • CRISPR-based therapy successes suggest a favorable regulatory environment for Verve.
  • Strategic partnerships with large pharma can accelerate Verve's development and commercialization.

What critics are saying

  • Potential competition from Vertex and CRISPR Therapeutics could overshadow Verve's advancements.
  • Most CRISPR therapies are in early stages, delaying Verve's path to approval.
  • Recent stock price drop may reflect investor concerns about Verve's financial stability.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on single-course gene editing for cardiovascular diseases.
  • The company targets well-validated genes PCSK9 and ANGPTL3 for lipid lowering.
  • Verve's approach shifts treatment from chronic management to potentially curative solutions.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE